Arlo Technologies, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Arlo Technologies, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $232.84M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $187.50M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $167.56M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $136.04M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $108.04M | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | $24.54M | Feb 26, 2021 |
| FY2020 | Sep 27, 2020 | $21.41M | Feb 26, 2021 |
| FY2020 | Jun 28, 2020 | $5.49M | Feb 26, 2021 |
| FY2020 | Mar 29, 2020 | $3.95M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $13.71M | Feb 26, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.93M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($30.50M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($22.04M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($56.63M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($56.03M) | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | ($15.21M) | Feb 26, 2021 |
| FY2020 | Sep 27, 2020 | ($17.46M) | Feb 26, 2021 |
| FY2020 | Jun 28, 2020 | ($29.26M) | Feb 26, 2021 |
| FY2020 | Mar 29, 2020 | ($39.33M) | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $19.62M | Feb 26, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.07M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($34.89M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($24.90M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($56.88M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($60.14M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($104.86M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | ($85.22M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | ($74.77M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $5.73M | Feb 28, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $73.65M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $73.18M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $68.65M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $64.71M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $59.06M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $60.14M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $69.38M | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | $58.79M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $34.68M | Feb 28, 2020 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $78.72M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $51.31M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $38.30M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($45.96M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | ($23.20M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | ($46.53M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $9.17M | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | ($17.69M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | ($38.99M) | Feb 28, 2020 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $2.69M | Feb 27, 2025 |
| FY2024 | Dec 31, 2023 | $2.85M | Feb 27, 2025 |
| FY2024 | Dec 31, 2022 | $2.01M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $2.27M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $3.89M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $6.66M | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | $21.67M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $3.58M | Feb 28, 2020 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $310.55M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $298.40M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $285.54M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $272.20M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $347.49M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $413.97M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $542.71M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $595.95M | Feb 28, 2020 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $182.71M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $197.49M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $182.26M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $184.51M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $234.84M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $280.20M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $339.34M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $326.44M | Feb 28, 2020 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $127.84M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $100.91M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $103.28M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $87.70M | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $112.65M | Feb 27, 2025 |
| FY2023 | Dec 31, 2020 | $133.77M | Feb 29, 2024 |
| FY2022 | Dec 31, 2019 | $203.38M | Mar 7, 2023 |
| FY2021 | Dec 31, 2018 | $269.50M | Mar 2, 2022 |
| FY2020 | Dec 31, 2017 | $125.42M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $73.17M | Feb 28, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.04M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $11.04M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $11.04M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $11.04M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | $11.04M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | $11.04M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | $11.04M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $15.64M | Feb 28, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($383.04M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($397.97M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($367.46M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($345.43M) | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | ($288.80M) | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | ($232.77M) | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | ($131.52M) | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | ($45.85M) | Feb 28, 2020 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $146.44M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $82.03M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $56.52M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $84.02M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $175.75M | Feb 29, 2024 |
| FY2022 | Dec 31, 2020 | $186.13M | Mar 7, 2023 |
| FY2021 | Dec 31, 2019 | $236.68M | Mar 2, 2022 |
| FY2020 | Dec 31, 2018 | $151.29M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $108.0K | Feb 28, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Sep 27, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Jun 28, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Mar 29, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 26, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Feb 29, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Sep 27, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Jun 28, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Mar 29, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 26, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 105.03M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 100.89M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 95.38M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 88.89M | Feb 29, 2024 |
| FY2022 | Dec 31, 2021 | 84.45M | Mar 7, 2023 |
| FY2021 | Dec 31, 2020 | 79.34M | Mar 2, 2022 |
| FY2020 | Dec 31, 2019 | 75.79M | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | 74.25M | Feb 28, 2020 |